{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:24:45Z","timestamp":1795026285500,"version":"4.10.2"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"23","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Key Technical Research Projects of Cell Therapy","award":["NCTIB2023XB01003"],"award-info":[{"award-number":["NCTIB2023XB01003"]}]},{"DOI":"10.13039\/501100015217","name":"National Key Laboratory of Aerodynamic Design and Research","doi-asserted-by":"publisher","award":["2023YFC3403700"],"award-info":[{"award-number":["2023YFC3403700"]}],"id":[{"id":"10.13039\/501100015217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>V\u03b41T cells, a rare subset of \u03b3\u03b4T cells, hold promise for treating solid tumors. Unlike conventional T cells, they recognize tumor antigens independently of the MHC antigen presentation pathway, making them a potential \u201coff-the-shelf\u201d cell therapy product. However, isolation and activation of V\u03b41T cells is challenging, which has limited their clinical investigation. Here, we developed a large-scale clinical-grade manufacturing process for V\u03b41T cells and validated the therapeutic potential of B7-H3 chimeric antigen receptor (CAR)\u2013modified V\u03b41T cells in treating solid tumors. Coexpression of IL2 with the B7-H3-CAR led to durable antitumor activity of V\u03b41T cells in vitro and in vivo. In multiple subcutaneous and orthotopic mouse xenograft tumor models, a single intravenous administration of the CAR-V\u03b41T cells resulted in complete tumor regression. These modified cells demonstrated significant in vivo expansion and robust homing ability to tumors, akin to natural tissue-resident immune cells. Additionally, the B7-H3-CAR-V\u03b41T cells exhibited a favorable safety profile. In conclusion, B7-H3-CAR\u2013modified V\u03b41T cells represent a promising strategy for treating solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A clinical-grade expansion protocol enabled generation of B7-H3\u2013targeted CAR-V\u03b41T cells with robust anticancer activity and a favorable safety profile, supporting the potential of CAR-V\u03b41T cells as an \u201coff-the-shelf\u201d therapy for solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-24-0195","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:04:12Z","timestamp":1725624252000},"page":"4066-4080","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["B7-H3\u2013Targeted CAR-V\u03b41T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors"],"prefix":"10.1158","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5996-7117","authenticated-orcid":false,"given":"Licui","family":"Jiang","sequence":"first","affiliation":[{"name":"1Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3636-5234","authenticated-orcid":false,"given":"Fengtao","family":"You","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4809-6746","authenticated-orcid":false,"given":"Hai","family":"Wu","sequence":"additional","affiliation":[{"name":"1Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3768","authenticated-orcid":false,"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7365-3629","authenticated-orcid":false,"given":"Shufen","family":"Xiang","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5794-690X","authenticated-orcid":false,"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"4PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9138-5383","authenticated-orcid":false,"given":"Huimin","family":"Meng","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0113-3422","authenticated-orcid":false,"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"4PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4717-8265","authenticated-orcid":false,"given":"Jiequn","family":"Huang","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6577-6420","authenticated-orcid":false,"given":"Yafen","family":"Li","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6236-6561","authenticated-orcid":false,"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2033-2005","authenticated-orcid":false,"given":"Gangli","family":"An","sequence":"additional","affiliation":[{"name":"1Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8139-4696","authenticated-orcid":false,"given":"Nan","family":"Yang","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0165-039X","authenticated-orcid":false,"given":"Bozhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."},{"name":"4PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4028-9801","authenticated-orcid":false,"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"1Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China."},{"name":"2PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China."},{"name":"4PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"2026042309580987200_bib1","article-title":"Cancer","author":"World Health Organization (WHO)"},{"key":"2026042309580987200_bib2","doi-asserted-by":"crossref","first-page":"984864","DOI":"10.3389\/fimmu.2022.984864","article-title":"Chimeric antigen receptor T cells applied to solid tumors","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"2026042309580987200_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042309580987200_bib4","article-title":"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma","author":"U.S. FOOD & Drug Administration"},{"key":"2026042309580987200_bib5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042309580987200_bib6","doi-asserted-by":"crossref","first-page":"188930","DOI":"10.1016\/j.bbcan.2023.188930","article-title":"Time to abandon CAR-T monotherapy for solid tumors","volume":"1878","author":"Yin","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026042309580987200_bib7","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/cancers15071935","article-title":"Empowering the potential of CAR-T cell immunotherapies by epigenetic reprogramming","volume":"15","author":"Alvanou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026042309580987200_bib8","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"2026042309580987200_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13287-022-02819-x","article-title":"Hurdles to breakthrough in CAR T cell therapy of solid tumors","volume":"13","author":"Marofi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2026042309580987200_bib10","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"2026042309580987200_bib11","doi-asserted-by":"crossref","first-page":"215840","DOI":"10.1016\/j.canlet.2022.215840","article-title":"Neoantigen-targeted TCR-T cell therapy for solid tumors: how far from clinical application","volume":"546","author":"Xu","year":"2022","journal-title":"Cancer Lett"},{"key":"2026042309580987200_bib12","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026042309580987200_bib13","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026042309580987200_bib14","doi-asserted-by":"crossref","first-page":"915837","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front Immunol"},{"key":"2026042309580987200_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042309580987200_bib16","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","article-title":"Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies","volume":"20","author":"Deniger","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026042309580987200_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","article-title":"Human gamma delta T cells: evolution and ligand recognition","volume":"296","author":"Adams","year":"2015","journal-title":"Cell Immunol"},{"key":"2026042309580987200_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development?","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"2026042309580987200_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2026042309580987200_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","article-title":"Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2026042309580987200_bib21","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026042309580987200_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"2026042309580987200_bib23","doi-asserted-by":"crossref","first-page":"eaax9364","DOI":"10.1126\/scitranslmed.aax9364","article-title":"An innate-like V\u03b41+ \u03b3\u03b4 T cell compartment in the human breast is associated with remission in triple-negative breast cancer","volume":"11","author":"Wu","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026042309580987200_bib24","doi-asserted-by":"crossref","first-page":"eabb0192","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- and tumor-infiltrating \u03b3\u03b4 T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026042309580987200_bib25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s43018-022-00376-z","article-title":"A local human V\u03b41 T cell population is associated with survival in nonsmall-cell lung cancer","volume":"3","author":"Wu","year":"2022","journal-title":"Nat Cancer"},{"key":"2026042309580987200_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41416-023-02303-0","article-title":"Local \u03b3\u03b4 T cells: translating promise to practice in cancer immunotherapy","volume":"129","author":"Zlatareva","year":"2023","journal-title":"Br J Cancer"},{"key":"2026042309580987200_bib27","doi-asserted-by":"crossref","first-page":"863155","DOI":"10.3389\/fimmu.2022.863155","article-title":"A simple and robust single-step method for CAR-v\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy","volume":"13","author":"Ferry","year":"2022","journal-title":"Front Immunol"},{"key":"2026042309580987200_bib28","doi-asserted-by":"crossref","first-page":"e003441","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042309580987200_bib29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","article-title":"Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells","volume":"14","author":"Knight","year":"2012","journal-title":"Cytotherapy"},{"issue":"Suppl 16","key":"2026042309580987200_bib30","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"40","author":"Neelapu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026042309580987200_bib31","doi-asserted-by":"crossref","first-page":"188783","DOI":"10.1016\/j.bbcan.2022.188783","article-title":"To kill a cancer: targeting the immune inhibitory checkpoint molecule, B7-H3","volume":"1877","author":"Kanchan","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026042309580987200_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026042309580987200_bib33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00262-021-03097-x","article-title":"Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy","volume":"71","author":"Liu","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2026042309580987200_bib34","doi-asserted-by":"crossref","first-page":"651634","DOI":"10.3389\/fimmu.2021.651634","article-title":"Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy","volume":"12","author":"Khan","year":"2021","journal-title":"Front Immunol"},{"key":"2026042309580987200_bib35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"2026042309580987200_bib36","doi-asserted-by":"crossref","first-page":"108153","DOI":"10.1016\/j.intimp.2021.108153","article-title":"The role of B7-H3 in tumors and its potential in clinical application","volume":"101","author":"Feng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2026042309580987200_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"key":"2026042309580987200_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jleuko\/qiad128","article-title":"Reprogramming of human \u03b3\u03b4 T cells by expression of an anti-CD19 TCR fusion construct (\u03b5TRuC) to enhance tumor killing","volume":"115","author":"Juraske","year":"2024","journal-title":"J Leukoc Biol"},{"key":"2026042309580987200_bib39","doi-asserted-by":"crossref","first-page":"108935","DOI":"10.1016\/j.intimp.2022.108935","article-title":"New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases","volume":"110","author":"Jin","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2026042309580987200_bib40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"2026042309580987200_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2026042309580987200_bib42","doi-asserted-by":"crossref","first-page":"914839","DOI":"10.3389\/fimmu.2022.914839","article-title":"Targeting cytokine signals to enhance \u03b3\u03b4T cell-based cancer immunotherapy","volume":"13","author":"Song","year":"2022","journal-title":"Front Immunol"},{"key":"2026042309580987200_bib43","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026042309580987200_bib44","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-0195\/3494291\/can-24-0195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/23\/4066\/3520107\/can-24-0195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/23\/4066\/3520107\/can-24-0195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:58:23Z","timestamp":1776952703000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/84\/23\/4066\/750179\/B7-H3-Targeted-CAR-V-1T-Cells-Exhibit-Potent-Broad"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":44,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,9,6]]},"published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-24-0195","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.32704380","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704371","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704392","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938308","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938314","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938302","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938323","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938317","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938305","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938326","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704398","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704389","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704395","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938320","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27938299","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704383","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704386","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704374","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7565485","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}